The article discusses the potential approval of psilocybin, the active ingredient in magic mushrooms, as a treatment for treatment-resistant depression (TRD) by the FDA, following successful results from Compass Pathways' clinical trials demonstrating significant symptom improvement in participants, highlighting the possibility of a new era in psychedelic medicine. #PsychedelicMedicine #MentalHealth #DepressionTreatment #USA
La psilocibina da el paso más importante de su historia médica moderna. El compuesto de los “hongos mágicos†supera ensayos decisivos y se acerca a una posible aprobación contra la depresión
